WALTHAM, Mass.–(BUSINESS WIRE)–Augmenix, Inc. a medical technology company that develops, manufactures,
and sells proprietary absorbable hydrogels that separate and protect
organs at risk during prostate radiotherapy, today announced that it
will participate in the 35th Annual J.P. Morgan Healthcare
Conference at the Westin St. Francis Hotel in San Francisco. John
Pedersen, Chief Executive Officer, is scheduled to present on Thursday,
January 12, 2017 at 9:30 a.m. Pacific Time in the Elizabethan D room.
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area
focused on the development and commercialization of radiation oncology
products using its proprietary hydrogel technology. The company was
founded by Incept LLC in 2008 and is funded by several leading venture
capital groups. More information about Augmenix can be found at http://www.Augmenix.com.
Eileen Gardner, RN, 781-902-1625